Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906035 · ClinicalTrials.gov registry record · NA
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
A NA study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00906035: Clinical Trial NA study, sponsored by University of Pennsylvania.
NCT00906035 is a NA study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00906035, a NA study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.
Primary Outcome
No analysis could be performed due to the insufficent number of participants enrolled. Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria.
Interventions
- DRUG Dipyridamole 200mg and Aspirin 25mg bid:
- DRUG Dipyridamole 200 mg bid
- DRUG Aspirin 25 mg bid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-09 |
| Est. Completion | 2010-04 |
| Phase | NA |
Why NCT00906035 stopped before completion
NCT00906035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Dipyridamole 200mg and Aspirin 25mg bid: is the first listed.
NCT00906035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00906035 about?
NCT00906035 is a clinical study titled "The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)". This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow ...
What is the current status of trial NCT00906035?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2002-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00906035?
The interventions under investigation include: Dipyridamole 200mg and Aspirin 25mg bid: (DRUG), Dipyridamole 200 mg bid (DRUG), Aspirin 25 mg bid (DRUG).
Who is sponsoring clinical trial NCT00906035?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00906035's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia